Castle Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $18.21
- Today's High:
- $18.815
- Open Price:
- $18.65
- 52W Low:
- $9.26
- 52W High:
- $36.095
- Prev. Close:
- $18.76
- Volume:
- 216424
Company Statistics
- Market Cap.:
- $311.22 million
- Book Value:
- 14.433
- Revenue TTM:
- $152.22 million
- Operating Margin TTM:
- -66.16%
- Gross Profit TTM:
- $105.03 million
- Profit Margin:
- -47.11%
- Return on Assets TTM:
- -14.45%
- Return on Equity TTM:
- -18.33%
Company Profile
Castle Biosciences Inc had its IPO on 2019-07-25 under the ticker symbol CSTL.
The company operates in the Healthcare sector and Diagnostics & Research industry. Castle Biosciences Inc has a staff strength of 542 employees.
Stock update
Shares of Castle Biosciences Inc opened at $18.65 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $18.21 - $18.82, and closed at $18.25.
This is a -2.72% slip from the previous day's closing price.
A total volume of 216,424 shares were traded at the close of the day’s session.
In the last one week, shares of Castle Biosciences Inc have slipped by -7.17%.
Castle Biosciences Inc's Key Ratios
Castle Biosciences Inc has a market cap of $311.22 million, indicating a price to book ratio of 1.5916 and a price to sales ratio of 5.258.
In the last 12-months Castle Biosciences Inc’s revenue was $152.22 million with a gross profit of $105.03 million and an EBITDA of $-89426000. The EBITDA ratio measures Castle Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Castle Biosciences Inc’s operating margin was -66.16% while its return on assets stood at -14.45% with a return of equity of -18.33%.
In Q1, Castle Biosciences Inc’s quarterly earnings growth was a negative -92.6% while revenue growth was a positive 56.6%.
Castle Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.5 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Castle Biosciences Inc’s profitability.
Castle Biosciences Inc stock is trading at a EV to sales ratio of 3.2511 and a EV to EBITDA ratio of -7.4044. Its price to sales ratio in the trailing 12-months stood at 5.258.
Castle Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $426.89 million
- Total Liabilities
- $30.14 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $3.34 million
- Dividend Payout Ratio
- 0%
Castle Biosciences Inc ended 2024 with $426.89 million in total assets and $0 in total liabilities. Its intangible assets were valued at $426.89 million while shareholder equity stood at $385.15 million.
Castle Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $30.14 million in other current liabilities, 27000.00 in common stock, $-190109000.00 in retained earnings and $10.70 million in goodwill. Its cash balance stood at $114.82 million and cash and short-term investments were $232.06 million. The company’s total short-term debt was $1,779,000 while long-term debt stood at $0.
Castle Biosciences Inc’s total current assets stands at $271.10 million while long-term investments were $0 and short-term investments were $117.23 million. Its net receivables were $27.73 million compared to accounts payable of $9.96 million and inventory worth $4.52 million.
In 2024, Castle Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $3.34 million.
Comparatively, Castle Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $18.25
- 52-Week High
- $36.095
- 52-Week Low
- $9.26
- Analyst Target Price
- $44.5
Castle Biosciences Inc stock is currently trading at $18.25 per share. It touched a 52-week high of $36.095 and a 52-week low of $36.095. Analysts tracking the stock have a 12-month average target price of $44.5.
Its 50-day moving average was $17.63 and 200-day moving average was $21.29 The short ratio stood at 7.72 indicating a short percent outstanding of 0%.
Around 436% of the company’s stock are held by insiders while 8456.1% are held by institutions.
Frequently Asked Questions About Castle Biosciences Inc
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.